BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Here's how 'Bridgerton' fans can watch the first episode of Season 4 before its Netflix release later this month - 2One third of Spanish pork export certificates blocked since swine fever outbreak, minister says
- 3What to know about voluntary chocolate recall
- 4Well known Worldwide Caf\u00e9s to Experience
- 5Putin says Russian forces will seize capital of Zaporizhzhya
- Simple Consideration Plants for Home and Office: An Aide
- Vote In favor of Your Number one Savvy Beds
- Explainer-What will change with the US reclassification of marijuana?
- Spanish police and soldiers track boars, reinforce farm security amid swine fever outbreak
- The Best 15 Applications for Efficiency and Association
- Picking Childcare Administrations for Your Loved ones
- Instructions to Boost Your True capacity with a Brain research Degree
- How one man's concern saved his brothers from heart disease
- What is the Significant Tech Expertise to Master Today?
